MLTX Latest Press Releases

-- November 4, 2026 --

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update Globe Newswire 7:00 AM

-- August 10, 2026 --

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results Globe Newswire 7:00 AM

-- June 23, 2026 --

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering Globe Newswire 11:08 PM

-- June 22, 2026 --

MoonLake Immunotherapeutics Announces Proposed Public Offering Globe Newswire 4:01 PM

-- June 21, 2026 --

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Globe Newswire 5:00 PM

Market Data Delayed 15 Minutes